BioCentury | Nov 2, 2015
Emerging Company Profile

Targeted disruption

...interaction Disease focus: Cancer Clinical status: Preclinical Founded: 2014 by Antoine Prestat, Didier Decaudin, Fariba Némati...
BioCentury | Aug 19, 2015
Company News

Management tracks

Anemia and asthma play Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) named Louis Matis SVP and chief development officer. Matis was executive director of strategic evaluation at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Cardiovascular company Armetheon Inc. (Milpitas, Calif.) named...
BioCentury | Nov 4, 2013
Clinical News

Latanoprost punctal plug delivery system: Phase II started

...April, Mati acquired assets related to QLT's punctal plug delivery system (see BioCentury, April 15). Mati Therapeutics Inc....
BioCentury | Apr 15, 2013
Company News

Mati Therapeutics Inc., QLT deal

...QLT announced that Mati exercised its option to acquire assets related to QLT's punctal plug delivery...
...punctal plug delivery system. Last December, QLT granted Mati the exclusive option for $500,000 and Mati...
...for open-angle glaucoma and ocular hypertension (see BioCentury, Dec. 3, 2012 & Jan. 7, 2013). Mati Therapeutics Inc....
BioCentury | Jan 7, 2013
Company News

Mati Therapeutics Inc., QLT deal

...On Dec. 24, 2012, QLT said it granted Mati an exclusive, 90-day option to acquire assets...
...exclusive, 90-day option to acquire assets related to QLT's punctal plug delivery system for $500,000. Mati...
...for up to three successive 30-day periods for an additional $100,000 payment per extension. If Mati...
BioCentury | Oct 14, 2002
Tools & Techniques

Knock in to knock out

Kinases are often part of a complex and adaptable cell signaling network, which makes target validation challenging. Cellular Genomics Inc. believes it can speed up kinase target validation using its analog sensitive kinase allele (ASKA)...
BioCentury | Oct 15, 2001
Company News

Cellular Genomics management update

Cellular Genomics Inc., Branford, Conn. Business: Genomics, Functional genomics, Proteomics Promoted: Louis Matis to CEO while remaining president; and Mark Velleca to VP from senior director of research WIR Staff...
BioCentury | Oct 10, 2001
Company News

Cellular Genomics names Matis as CEO

Louis Matis, president of drug discovery company Cellular Genomics (Branford, Conn.), assumed the additional position of CEO. BC Staff...
BioCentury | Jan 29, 2001
Emerging Company Profile

Corporate Profile

Cellular Genomics Inc. New Haven, Conn. Technology: Whole genome approach to select and validate targets Disease focus: Cancer, autoimmune, inflammatory, infectious disease, CNS, and metabolic diseases Clinical status: Research Founded: 1998 by Ira Mellman Corporate...
BioCentury | Jan 29, 2001
Emerging Company Profile

Corporate Profile

Cellular Genomics Inc. New Haven, Conn. Technology: Whole genome approach to select and validate targets Disease focus: Cancer, autoimmune, inflammatory, infectious disease, CNS, and metabolic diseases Clinical status: Research Founded: 1998 by Ira Mellman Corporate...
Items per page:
1 - 10 of 14
BioCentury | Nov 2, 2015
Emerging Company Profile

Targeted disruption

...interaction Disease focus: Cancer Clinical status: Preclinical Founded: 2014 by Antoine Prestat, Didier Decaudin, Fariba Némati...
BioCentury | Aug 19, 2015
Company News

Management tracks

Anemia and asthma play Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) named Louis Matis SVP and chief development officer. Matis was executive director of strategic evaluation at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Cardiovascular company Armetheon Inc. (Milpitas, Calif.) named...
BioCentury | Nov 4, 2013
Clinical News

Latanoprost punctal plug delivery system: Phase II started

...April, Mati acquired assets related to QLT's punctal plug delivery system (see BioCentury, April 15). Mati Therapeutics Inc....
BioCentury | Apr 15, 2013
Company News

Mati Therapeutics Inc., QLT deal

...QLT announced that Mati exercised its option to acquire assets related to QLT's punctal plug delivery...
...punctal plug delivery system. Last December, QLT granted Mati the exclusive option for $500,000 and Mati...
...for open-angle glaucoma and ocular hypertension (see BioCentury, Dec. 3, 2012 & Jan. 7, 2013). Mati Therapeutics Inc....
BioCentury | Jan 7, 2013
Company News

Mati Therapeutics Inc., QLT deal

...On Dec. 24, 2012, QLT said it granted Mati an exclusive, 90-day option to acquire assets...
...exclusive, 90-day option to acquire assets related to QLT's punctal plug delivery system for $500,000. Mati...
...for up to three successive 30-day periods for an additional $100,000 payment per extension. If Mati...
BioCentury | Oct 14, 2002
Tools & Techniques

Knock in to knock out

Kinases are often part of a complex and adaptable cell signaling network, which makes target validation challenging. Cellular Genomics Inc. believes it can speed up kinase target validation using its analog sensitive kinase allele (ASKA)...
BioCentury | Oct 15, 2001
Company News

Cellular Genomics management update

Cellular Genomics Inc., Branford, Conn. Business: Genomics, Functional genomics, Proteomics Promoted: Louis Matis to CEO while remaining president; and Mark Velleca to VP from senior director of research WIR Staff...
BioCentury | Oct 10, 2001
Company News

Cellular Genomics names Matis as CEO

Louis Matis, president of drug discovery company Cellular Genomics (Branford, Conn.), assumed the additional position of CEO. BC Staff...
BioCentury | Jan 29, 2001
Emerging Company Profile

Corporate Profile

Cellular Genomics Inc. New Haven, Conn. Technology: Whole genome approach to select and validate targets Disease focus: Cancer, autoimmune, inflammatory, infectious disease, CNS, and metabolic diseases Clinical status: Research Founded: 1998 by Ira Mellman Corporate...
BioCentury | Jan 29, 2001
Emerging Company Profile

Corporate Profile

Cellular Genomics Inc. New Haven, Conn. Technology: Whole genome approach to select and validate targets Disease focus: Cancer, autoimmune, inflammatory, infectious disease, CNS, and metabolic diseases Clinical status: Research Founded: 1998 by Ira Mellman Corporate...
Items per page:
1 - 10 of 14